These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21883990)

  • 21. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Latest clinical data on testing for high on-treatment platelet reactivity.
    Fileti L; Campo G; Valgimigli M
    Rev Cardiovasc Med; 2011; 12 Suppl 1():S14-22. PubMed ID: 22080983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of prasugrel in a patient with clopidogrel hypersensitivity.
    Peppard SR; Held-Godgluck BM; Beddingfield R
    Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
    Hochholzer W; Trenk D; Mega JL; Morath T; Stratz C; Valina CM; O'Donoghue ML; Bernlochner I; Contant CF; Guo J; Sabatine MS; Schömig A; Neumann FJ; Kastrati A; Wiviott SD; Sibbing D
    Am Heart J; 2011 Sep; 162(3):518-26.e5. PubMed ID: 21884870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    Wenaweser P; Windecker S; Billinger M; Cook S; Togni M; Meier B; Haeberli A; Hess OM
    Am J Cardiol; 2007 Feb; 99(3):353-6. PubMed ID: 17261397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
    Gurbel PA; Antonino MJ; Tantry US
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):989-1004. PubMed ID: 19575629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?
    Cattaneo M
    J Thromb Haemost; 2012 Mar; 10(3):327-36. PubMed ID: 22221409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to anti-platelet agents.
    Cattaneo M
    Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the pharmacogenetics of clopidogrel.
    Cuisset T; Morange PE; Alessi MC
    Hum Genet; 2012 May; 131(5):653-64. PubMed ID: 22207144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel pharmacogenetics and its clinical implications.
    Singh M; Thapa B; Arora R
    Am J Ther; 2010; 17(3):e66-73. PubMed ID: 19636246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug insight: Clopidogrel nonresponsiveness.
    Gurbel PA; Tantry US
    Nat Clin Pract Cardiovasc Med; 2006 Jul; 3(7):387-95. PubMed ID: 16810174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel in acute coronary syndrome: implications of recent study findings.
    Duerschmied D; Bode C; Moser M
    Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1215-29. PubMed ID: 20828343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel "resistance": where are we now?
    Qureshi Z; Hobson AR
    Cardiovasc Ther; 2013 Feb; 31(1):3-11. PubMed ID: 21884029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.